Vaccine Makers See Hope Despite Brutal Market Run

It is an unusual time to be in the vaccine business, according to industry leaders gathered at the BIO conference this week. But their outlook is not altogether bleak. Despite a brutal financial stretch for many vaccine companies, executives say they still see reasons for optimism. The conference, a major industry event, has become a platform for discussing both the challenges and the potential paths forward. The key message from attendees is resilience. While the market has been punishing, the long-term need for vaccines remains strong. Companies are focusing on innovation and new pipelines to weather the current storm. For now, the industry is bracing for more hardship, but not surrendering to it.